Korean J Pain 2014; 27(3): 297-300
Published online July 31, 2014 https://doi.org/10.3344/kjp.2014.27.3.297
Copyright © The Korean Pain Society.
Jose Jesus Monsivais*, and Diane Burn Monsivais
Hand and Microsurgery Center of El Paso, Orthopedics and Rehabilitation, Texas Tech University Health Science Center (TTUHSC), Texas, USA.
Correspondence to: Jose Jesus Monsivais. Hand and Microsurgery Center of El Paso, Orthopedics and Rehabilitation, Texas Tech University Health Science Center (TTUHSC), 10175 Gateway West, Suite 230, El Paso, Texas 79925, USA. Tel: +1-915-590-3666, Fax: +1-915-590-3667, email@example.com
Received: June 11, 2014; Accepted: June 13, 2014
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
This report describes the long term safety and efficacy of intrathecal therapy using Sufentanil for the management of chronic intractable neuropathic pain in 12 chronic pain patients. Standardized psychological screening was used to determine treatment suitability. Evaluation data included the Visual Analog Scale (VAS), Wong-Baker Faces Scale, Brief Pain Inventory (BPI), Disability of Arm, Shoulder, and Hand (DASH), McGill Quality of Life Questionnaire, and complications (granulomas, toxicity, withdrawal, or deaths). SPSS version 18 was used for data analysis. Pre- and post- treatment BPI measures and pain scale scores showed a statistically significant difference. There were no complications directly related to drug toxicity, nor drug withdrawals, granulomas, or deaths. Intrathecal therapy with Sufentanil therapy offers a good treatment alternative for those cases that have failed both surgery and standard pain treatment. Strict patient selection based on psychological screening, control of co-morbidities, a proper pain management may contribute to successful outcome.
Keywords: implantable infusion pump, intractable pain, neuropathic pain, sufentanil